Phibro Animal Health Corporation (NASDAQ:PAHC) recently announced that it is pursuing patent protection, following a key milestone in its current development of a vaccine for African Swine Fever (ASF). The identification of a group of peptides and proteins is a crucial step toward Phibro’s development of a solution for this disease.
More on the Development Process
This advancement in the vaccine development process involves the detection of immunogenic epitopes and proteins that have the potential to form the basis for a vaccine against ASF.
Using a unique bioinformatics analysis tool, Phibro’s R&D team made this identification in order to select the highest potential epitopes and proteins capable of prompting protective immune response.
The company aims to create a specific epitope-based vaccine rather than following the traditional path of a weakened live vaccine. If successful, this approach will not only be an efficient response to ASF but will also create a vaccine that does not threaten the risk of spreading the disease.
Recent Developments
Lately, Phibro has been investing in R&D and expanding its product portfolio to improve broiler health and increase yield.
In February 2019, the company announced that it will be introducing Provia Prime direct-fed microbial product that helps optimize the gut microbiome for better health, immunity and productivity in poultry. Provia Prime is in a class of Bacillus-based Direct Fed Microbials that have been clinically verified to promote beneficial gut bacteria, which can help enhance immunity, improve gut health and act as natural growth promoters.
Price Performance
In the past year, the stock has declined 30.6% against the industry’s 7.2% rise.
Zacks Rank and Key Picks
Phibro currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical space are Teleflex Inc. (NYSE:TFX) , Penumbra (NYSE:PEN) and Bruker Corporation (NASDAQ:BRKR) . While Penumbra sports a Zacks Rank #1 (Strong Buy), the other two companies carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Teleflex’s long-term earnings growth rate is expected to be 13.7%.
Penumbra’s long-term earnings growth rate is projected at 21.5%.
Bruker’s long-term earnings growth rate is estimated at 12.6%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report
Teleflex Incorporated (TFX): Free Stock Analysis Report
Bruker Corporation (BRKR): Free Stock Analysis Report
Penumbra, Inc. (PEN): Free Stock Analysis Report
Original post
Zacks Investment Research